Breast Cancer Clinical Trial
A Pilot Study to Evaluate the Efficacy of Fosaprepitant and Granisetron Transdermal System for the Prevention of Acute and Delayed Nausea and Vomiting in Breast Cancer Patients and to Identify Predictors of Response
|Source||University of Southern California|
|Start date||September 4, 2012|
|Completion date||September 4, 2018|
This clinical trial studies how well fosaprepitant dimeglumine and granisetron transdermal system work in preventing nausea and vomiting in patients with breast cancer undergoing chemotherapy. Antiemetic drugs may help lessen or prevent nausea and vomiting in patients treated with chemotherapy
I. To evaluate the efficacy of the combination of fosaprepitant (fosaprepitant dimeglumine) and granisetron transdermal system in the prevention of acute and delayed chemotherapy induced nausea and vomiting in breast cancer patients undergoing adjuvant or neoadjuvant chemotherapy.
I. To evaluate the safety of the combination of fosaprepitant and granisetron transdermal system in breast cancer patients undergoing adjuvan or neoadjuvant chemotherapy.
I. To explore the use of single nucleotide polymorphisms (SNPs) in the 5âhydroxytryptamine-3 (5HT3) and neurokinin-1 (NK-1) receptors as potential markers of efficacy.
OUTLINE: Patients receive granisetron transdermal system patch 24-48 hrs before the initiation of chemotherapy. Patients wear the granisetron transdermal system patch for 7 days. Patients receive fosaprepitant dimeglumine intravenously (IV) over 15 minutes on day 1 of chemotherapy. Treatment repeats every 2 or 3 weeks for up to 4 courses in the absence of unacceptable toxicity.
|Completed||NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data||N/A|
|Recruiting||NCT01857193 - Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer||Phase 1|
|Completed||NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis||N/A|
|Active, not recruiting||NCT02371174 - Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan.||N/A|
|Completed||NCT01881230 - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)||Phase 2/Phase 3|
|Recruiting||NCT01967823 - T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer||Phase 2|
|Recruiting||NCT02739425 - The Efficacy of Sentimag in Detection of Sentinel Node Biopsy||N/A|
|Not yet recruiting||NCT03176888 - Health Benefits of HIT for Breast Cancer Patients||N/A|
|Not yet recruiting||NCT02767661 - Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer||Phase 3|
|Recruiting||NCT02689427 - Phase IIB Neoadjuvant Enzalutamide (ZT) Plus Taxol for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer (AR+ TNBC)||Phase 2|
|Recruiting||NCT02980848 - Assessing Breast Density's Value in Imaging - A Comparative Effectiveness Study||N/A|
|Recruiting||NCT02897635 - Integrative Approaches For Cancer Survivorship 2: Project 1||N/A|
|Recruiting||NCT02934126 - The Development of a Personalized Decision Aid: Perspectives of Patients and Health Care Professionals on Shared Decision Making and Informational Needs on Radiotherapy for Breast Cancer||N/A|
|Recruiting||NCT02897544 - Integrative Approaches for Cancer Survivorship 2: Project 2||N/A|
|Recruiting||NCT02035085 - 19F Hot Spot MRI of Human Adipose-derived Stem Cells for Breast Reconstruction||Phase 1|
|Recruiting||NCT02897050 - Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer||Phase 2|
|Recruiting||NCT02909751 - Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer||Phase 2|
|Recruiting||NCT02840344 - Couples-Based Mindfulness for Young Breast Cancer Survivors||N/A|
|Recruiting||NCT02894398 - Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant||Phase 2|
|Recruiting||NCT02903524 - Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer||Phase 4|